Vera Therapeutics (VERA) Net Income towards Common Stockholders (2020 - 2026)
Vera Therapeutics (VERA) posted Net Income towards Common Stockholders of -$288.2 million for Q1 2026, down 206.24% on a QoQ basis from -$94.1 million in Q4 2025, and down 365.36% year-over-year from $108.6 million in Q1 2025.
Vera Therapeutics (VERA) Net Income towards Common Stockholders (2020 - 2026) Analysis & Trends
Vera Therapeutics' Net Income towards Common Stockholders history runs 7 years deep, the most recent figure standing at -$288.2 million for Q1 2026.
- Quarterly Net Income towards Common Stockholders fell 365.36% year-over-year to -$288.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$556.3 million (down 165.96% YoY) and the FY2025 annual result came in at $62.9 million, up 6292000.0% from the prior year.
- Net Income towards Common Stockholders was -$288.2 million for Q1 2026 at Vera Therapeutics, down from -$94.1 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at -$17.7 million in Q1 2022 and bottomed at -$288.2 million in Q1 2026.
- A 5-year average of -$60.1 million and a median of -$39.1 million in 2023 frame the typical range for Net Income towards Common Stockholders.
- Annual changes were most pronounced in 2023 — Net Income towards Common Stockholders rose 24.19% — and 2026, when it tumbled 365.36%.
- Vera Therapeutics' Net Income towards Common Stockholders stood at -$33.2 million in 2022, then declined by 17.67% to -$39.1 million in 2023, then dropped by 28.21% to -$50.1 million in 2024, then sank by 87.99% to -$94.1 million in 2025, then slumped by 206.24% to -$288.2 million in 2026.
- Business Quant data shows VERA's Net Income towards Common Stockholders at -$288.2 million in Q1 2026, -$94.1 million in Q4 2025, and -$81.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,899.61 Bn | 65,899.33 Bn | - | -625.73 |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - | - |
| 3 | Akari Therapeutics | 1,022.34 Bn | 1,022.34 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 472.68 Bn | 467.89 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 122.24 Bn | 114.99 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 70.08 Bn | 61.33 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.46 Bn | 62.46 Bn | - | -0.68 |
| 8 | Argenx Se | 55.93 Bn | 50.75 Bn | 1.41 Bn | 472.00 Mn |
| 9 | Alnylam Pharmaceuticals | 37.59 Bn | 34.58 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Vera Therapeutics | 2.56 Bn | 2.56 Bn | - | -288.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -288.25 Mn |
| Dec 31, 2025 | -94.13 Mn |
| Sep 30, 2025 | -81.42 Mn |
| Jun 30, 2025 | -92.52 Mn |
| Mar 31, 2025 | -61.94 Mn |
| Dec 31, 2024 | -50.07 Mn |
| Sep 30, 2024 | -53.00 Mn |
| Jun 30, 2024 | -44.16 Mn |
| Mar 31, 2024 | -33.50 Mn |
| Dec 31, 2023 | -39.05 Mn |
| Sep 30, 2023 | -25.26 Mn |
| Jun 30, 2023 | -21.01 Mn |
| Mar 31, 2023 | -30.51 Mn |
| Dec 31, 2022 | -33.19 Mn |
| Sep 30, 2022 | -33.32 Mn |
| Jun 30, 2022 | -23.44 Mn |
| Mar 31, 2022 | -17.65 Mn |
| Dec 31, 2021 | -16.60 Mn |
| Sep 30, 2021 | -7.25 Mn |
| Jun 30, 2021 | -5.85 Mn |